Synthetic inhibitors of galectins: Structures and syntheses

21Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

The recent discovery of the critical involvement of galectins in cancer progression, and in inflammatory and immune responses, has raised this family of β-D-galactoside-binding proteins to the rank of high-priority drug targets by the scientific community. This report will highlight the relevance of glycochemistry toward the efficient development of synthetic galectins inhibitors with high affinity and selectivity, as small molecules or multivalent glycoconjugates.

Cite

CITATION STYLE

APA

Denavit, V., Lainé, D., Tremblay, T., St-Gelais, J., & Giguère, D. (2018). Synthetic inhibitors of galectins: Structures and syntheses. Trends in Glycoscience and Glycotechnology. Gakushin Publishing Company. https://doi.org/10.4052/tigg.1729.1SE

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free